Equipment Trends in Advanced Solid-Dosage Drug Manufacturing: INTERPHEX Keynote Part 1
Dave DiProspero, director of Pharmaceutical Process Technology at CRB, spoke about equipment trends in solid-dosage drug manufacturing.
Equipment and advanced manufacturing approaches to meet the evolving needs for solid-dosage drugs include continuous manufacturing, containment strategies, Industry 4.0 tools, and techniques for optimizing solid dosage form manufacturing. “Equipment Trends in Advanced Solid-Dosage Drug Manufacturing” was part of a keynote series at INTERPHEX 2021 on Oct. 19, 2021.
The session was moderated by Jennifer Markarian, manufacturing editor, Pharmaceutical Technology, Pharmaceutical Technology Europe, and BioPharm International. In this video, Jennifer interviewed Dave DiProspero, Director Pharmaceutical Process Technology, CRB.
In the interview, Dave shared what he sees as key trends in manufacturing of oral solid dosage (OSD) drug forms. He gave his perspective on continuous manufacturing processes and containment equipment for OSD drugs.
This video is part 1 of 5. The other speakers in this session were:
- Part 2: Johannes Khinast, Institute for Process and Particle Engineering in the Research Center Pharmaceutical Engineering (RCPE) at the Graz University of Technology in Austria.
- Part 3: Fernando Muzzio, PhD, Distinguished Professor of Chemical and Biochemical Engineering at Rutgers University.
- Part 4: Sharon Nowak, Business Development Manager, Coperion K-Tron USA Food & Pharmaceutical Industries.
- Part 5: Gernot Warnke, Head of R&D, JRS Pharma.
Watch other videos in this keynote series:
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
